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ABSTRACT
Background Diabetes mellitus (DM) is associated with impaired prognosis in patients with heart failure (HF),
but pathogenic mechanisms are unclear. In the failing heart, elevated b-adrenergic receptor (b-AR) activation by
catecholamines causes G-protein-coupled receptor kinase-2 (GRK2) upregulation which is responsible for b-AR
signalling dysfunction. Importantly, GRK2 expression, measured in peripheral lymphocytes of HF patients,
correlates with levels of this kinase in the failing myocardium reflecting the loss of hemodynamic function.
Moreover, HF-related GRK2 protein overexpression promotes insulin resistance by interfering with insulin sig-
nalling. The aim of this study was to assess lymphocyte GRK2 protein levels in HF patients with and without
DM.
Methods and materials Patients with a diagnosis of HF were enrolled in the study. All subjects underwent a
complete clinical examination (including NYHA functional class assessment and echocardiography) and blood
draw for serum N-terminal pro-brain natriuretic peptide (NT-proBNP), lymphocyte GRK2 and plasma norepi-
nephrine (NE) levels. Demographic data including age, sex, medications, cardiovascular risk factors and pres-
ence of comorbidities were also collected.
Results Two hundred and sixty-eight patients with HF (left ventricular ejection fraction [LVEF] 306  76%)
with and without DM were enrolled. No differences between the two groups were found in terms of demog-
raphy, HF aetiology, LVEF, NYHA class, NE and NT-proBNP. GRK2 was significantly higher in patients with DM
compared to non-DM. At multivariate linear regression analysis, LVEF, NE, NT-proBNP and diabetes came out to
be independent predictors of GRK2 levels in the overall study population.
Conclusion In HF patients, DM is associated with significantly more elevated lymphocyte GRK2 protein levels,
likely reflecting more compromised cardiac b-AR signalling/function, despite similar hemodynamic status and
neuro-hormonal activation compared to patients without DM. These findings contribute to explain the negative
prognostic impact of DM in patients with HF.
Keywords Beta adrenergic receptor, diabetes, functional recovery, GRK2, heart failure, sympathetic nervous
system.
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Introduction
Despite advances in prevention and management, mortality
and morbidity due to chronic heart failure (HF) continue to
rise [1,2]. Diabetes mellitus (DM) has high prevalence in HF
patients and is associated with increased risk of cardiovas-
cular mortality [3–5]. Increased sympathetic nervous system
(SNS) activity and outflow represent a hallmark of chronic HF
[6,7]. Although this is initially an adaptive process to
compensate for decreased cardiac contractility, in the long
term, this mechanism becomes maladaptive [6]. In fact, it is
widely recognized that elevated circulating levels of cate-
cholamine are associated with poor prognosis in HF patients
[8,9]. It has now been three decades since Bristow and col-
laborators reported for the first time that cardiac b-adrenergic
receptor (b-AR) system is dysfunctional and inotropic reserve
is impaired in HF patients [10]. The excessive amount of
cardiac norepinephrine (NE) is an early trigger for enhanced
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G-protein-coupled receptor kinase-2 (GRK2) levels/activity,
that is mechanistically involved in the processes of cardiac b-
AR downregulation and desensitization during HF [11,12].
GRK2 is a serine–threonine kinase that phosphorylates acti-
vated G-protein-coupled receptors (GPCRs), leading to atten-
uation of intracellular b-AR signalling in the heart [11,12].
Several lines of evidence have reported that increased cardiac
GRK2 levels have a pathogenic role in HF progression [11–
13]. Importantly, GRK2 is also upregulated in peripheral
lymphocytes of HF patients, and peripheral lymphocyte levels
correlate with levels in failing heart, as well as, with the
degree of hemodynamic dysfunction and with HF severity
[14–16]. Notably, we demonstrated that exercise-induced
changes in blood GRK2 protein levels predict outcomes in HF
patients [17]. We also recently reported that DM patients with
HF show more severely reduced cardiac 123I-meta-iodoben-
zylguanidine (123I-MIBG) uptake compared to HF patients
without DM, supporting the notion that alteration in SNS
cardiac innervation might be related to the progression of
diabetic heart disease and worsen prognosis in HF patients
[18]. Indeed, both glucose and insulin are known to facilitate
sympathetic nervous activity and norepinephrine release [19].
In addition, a close relationship between GRK2 levels and
cardiac metabolism, including insulin resistance and reduced
glucose uptake during HF, has been reported [20]. In partic-
ular, GRK2 interacts with insulin receptor substrate 1 (IRS1),
leading to attenuation of insulin signalling in the myocyte
[20]. Thus, we hypothesized that lymphocytes GRK2 levels
would be increased in HF patients with DM compared to HF
patients without DM.
Methods
Study protocol was approved by the local ethical committee,
and all subjects gave written informed consent to participate in
the study. This study was conducted and written according to
the STROBE guidelines for observational studies in epidemi-
ology [21] and the broader EQUATOR guidelines [22].
Population
Patients with an established diagnosis of HF were enrolled at
Salvatore Maugeri Foundation, Scientific Institute of Telese
Terme (Telese Terme, BN, Italy) and at the Department of
Translational Medical Sciences of the University of Naples
‘Federico II’ during the study period (from December 2007 to
January 2009). Inclusion criteria were as follows: the diagnosis
of HF due to ischaemic or nonischaemic aetiology, left ven-
tricular ejection fraction (LVEF) ≤ 45% and clinical stability of
symptoms for at least 1 month prior to inclusion and guide-
line-based optimal pharmacotherapy. Exclusion criteria were
as follows: cardiac revascularization or acute myocardial
infarction within 3 months before study entry, uncontrolled
hypertension (> 180 mm Hg systolic or > 110 mm Hg diastolic
on measurements made on at least three separate dates during
the preceding 3 months), severe chronic kidney disease [glo-
merular filtration rate (GFR) < 30 mL/min], comorbidity con-
ditions associated with lymphocyte activation (i.e. cancer,
severe chronic diseases, ongoing infection and excessive alco-
hol intake) and a life expectancy of < 1 year, based on non-
cardiac reasons. The diagnosis of DM was confirmed by
clinical history or through the assessment of at least two
determinations of fasting plasma glucose ≥ 126 mg/dL or a
random plasma glucose test ≥ 200 mg/dL 120 min after an
oral glucose tolerance test.
At the time of enrolment, all subjects underwent a complete
clinical examination (including NYHA functional class assess-
ment and echocardiography) and blood draw for serum N-
terminal pro-brain natriuretic peptide (NT-proBNP), lympho-
cyte GRK2 and plasma NE levels. Demographic data including
age, sex, medications, cardiovascular risk factors and presence
of comorbidities were also collected.
NT-proBNP measurements
Serum NT-proBNP was measured by a radioimmunoassay test
kit produced by the Shionogi and Co. and distributed by Bayer
Corporation [17].
Lymphocyte GRK2 immunoblotting
Blood samples were collected from all patients in EDTA tubes.
Lymphocytes were isolated by ficoll gradient using HIST-
OPAQUE-1077 (Sigma, Milan, Italy), frozen and stored at
80 °C until the day of the assay. Immunodetection of GRK2
was performed using detergent-solubilized lymphocyte extracts
after immunoprecipitation (IP), as previously described [17].
Sample size
On the basis of previous study [14], we predicted an anticipated
effect size for b-adrenergic receptor signalling (lymphocyte
GRK2 level) equal to 015. Considering seven confounding
variables, a sample size of 136 subjects for each group was
estimated to detect a significant difference between the DM and
non-DM HF patients (two-tailed test) with a type I error of 5%
and a type II error of 10%.
Statistical analysis
Continuous variables are expressed as mean  standard devi-
ation and compared by the use of Student’s t-test (normally
distributed) or as median  interquartile range value and
compared by the use of Mann–Whitney U-test (not normally
distributed), as appropriate. Normality of data distribution was
evaluated using the Kolmogorov–Smirnov test. Not normally
distributed continuous variables were natural log transformed
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(NE, GRK2 and NT-proBNP). Categorical variables are
expressed as proportion and compared by use of chi-squared
test with risk ratios and 95% confidence intervals quoted.
Correlation between variables was determined with the Pear-
son correlation coefficient.
To determine the independent predictors of GRK2 levels,
linear regression analysis was performed and variables
achieving P < 010 on univariate analysis are then included in a
multivariate analysis. To fulfil the assumption of linearity of the
not normally distributed variables, the natural logarithmic
function of NE, GRK2 and NT-proBNP was used in the linear
regression analysis.
All data were collected in an Excel database and analysed by
SPSS version 190 (SPSS, Inc., Chicago, IL, USA). Statistical
significance was accepted at P < 005.
Results
Patient characteristics
Characteristics of the overall study population and of DM and
non-DM patients are shown in Table 1. Four patients were
excluded for missing lymphocyte GRK2 levels. The study
population consisted of 268 patients, 184 males (687%), with
mean age of 7152  102 years and with a mean LVEF of
306  76%. Patients in NYHA class II and III were 19% and
81%, respectively. HF was of ischaemic aetiology in 226 patients
(843%), while in 42 patients (157%), the aetiology was an idi-
opathic dilated cardiomyopathy. One hundred and thirty
patients (485%) had a diagnosis of type 2 DM. Patients with
DM and non-DM patients were comparable for demographic
characteristics, comorbidities, LVEF, NYHA class, plasma NE
Table 1 Characteristic of patients in the overall study population and in diabetic and nondiabetic patients
All No DM pts DM pts
P value(n = 268) (n = 138) (n = 130)
Age, y 7152  102 7131  107 7174  97 0733
Gender, male% (n) 687% (184) 725% (100) 646% (84) 0188
LVEF, % 306  76 311  72 3002  79 0243
Aetiology: Ischaemic, % (n) 843% (226) 812% (112) 877% (114) 0179
NYHA class, % (n) II = 19% (51) II = 21% (29) II = 169% (22) 0438
III = 81% (217) III = 79 % (109) III = 831% (108)
Hypertension, % (n) 78% (209) 703% (97) 862% (112) 0002
Hypercholesterolaemia, % (n) 34% (91) 304% (42) 377% (49) 0246
GFR < 60 mL/mg, % (n) 392% (105) 377% (52) 408% (53) 0619
ACE-I/ARBs, % (n) 836% (224) 797% (110) 877% (114) 0099
b-blockers, % (n) 519% (139) 478% (66) 562% (73) 0181
Diuretics, % (n) 716% (192) 688% (95) 746% (97) 0343
CCBs, % (n) 228% (61) 174% (24) 285% (37) 0041
NT-proBNP, pg/dL† 17535 (1100–25437) 1563 (9322–24707) 1900 (12082–25692) 0222
Plasma norepinephrine, pg/dL† 6225 (406–7535) 611 (3857–754) 6255 (4377–7512) 0662
Antidiabetic therapy
Diet % (n) – – 362% (47) –
Oral antidiabetic agents % (n) – – 469% (61) –
Insulin % (n) – – 69% (9) –
Oral agents + Insulin % (n) – – 10% (13) –
DM, diabetes mellitus; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; GFR, glomerular filtration rate; ACE-I, angiotensin-converting-
enzyme inhibitor; ARBs, angiotensin receptor blockers; CCBs, calcium channel blockers; NT-proBNP, N-terminal pro-brain natriuretic peptide.
†Data are expressed as median and interquartile range value (not normal distributed).
Data are expressed as mean  1 standard deviation or percentage (normal distributed).
P value is referred to difference between diabetic and nondiabetic patients.
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levels and serum NT-proBNP levels with no statistical differ-
ences between the two groups (Table 1). No statistically sig-
nificant differences between HF patients with and without DM
were found for cardiovascular risk factors with the only
exception of hypertension. In fact, in the DM group, 112
patients (862%) had hypertension with a higher prevalence
than in non-DM patients (703%, P = 0002). DM and non-DM
patients did not differ in terms of HF therapy, with the excep-
tion of more frequent calcium channel blockers (CCBs) use in
patients with DM. In patients with DM, 61 patients (469%)
were treated with oral antidiabetic drugs, 9 patients (69%) with
insulin alone, 13 patients (10%) with the association of oral
drugs and insulin and 47 (362%) only with diet.
Lymphocyte GRK2 protein levels in DM and non-DM
HF patients
LymphocyteGRK2protein levelswere significantly higher inHF
patients with DM (149  056 D.U.) compared to HF patients
without DM (136  078 D.U.; P = 0003) (Fig. 1). In all 268 HF
patients, age, LVEF, NYHA functional class, presence of DM,
GFR, serum NT-proBNP levels, plasma NE levels, therapy with
diuretics were predictors of lymphocyte GRK2 protein levels in
univariate analysis (Table 2). At multivariate analysis, only
LVEF, presence of DM, NT-proBNP and NE levels remained
significantly correlated with blood GRK2 levels (Table 2).
Determinants of lymphocyte GRK2 protein levels in
HF patients without DM
In the group of HF patients without DM, in univariate analysis,
lymphocytes GRK2 protein levels significantly correlated with
age, LVEF, NYHA functional class, GFR, NT-proBNP, NE,
therapy with b-blockers, CCBs and diuretics (Table 3a). At
multivariate analysis, LVEF, NT-proBNP and NE remained
significantly correlated with blood GRK2 levels (Table 3a).
Determinants of lymphocyte GRK2 protein levels in
HF patients with DM
In the group of HF patients with DM, in univariate analysis,
lymphocytes GRK2 protein levels significantly correlated with
LVEF and therapy with ACE inhibitors/angiotensin receptor
blockers (Table 3b). At multivariate analysis, only LVEF
remained significantly correlated with blood GRK2 levels
(Table 3b). In a subgroup of 60 HF patients with DM, lym-
phocyte GRK2 protein levels significantly correlated with
HbA1c (Pearson = 0390 P = 0002) (Figure S1). Demographic
and clinical characteristics of this subpopulation of HF patients
with DM are shown in the Table S1. In the same subgroup of
patients, a borderline significant correlation was found between
blood GRK2 levels and DM duration (Pearson = 0245
P = 0059) (Figure S2).
Discussion
The findings of the present study indicate that lymphocyte
levels of GRK2 protein are more elevated in DM patients with
HF, compared to non-DM HF patients, likely reflecting more
compromised b-AR status.
Previous studies
Despite various mechanisms have been proposed, including
the effects of altered glycemic control on the development of
coronary atherosclerosis and the existence of a specific diabetic
cardiomyopathy related to microangiopathy, the pathogenic
mechanisms linking DM to HF remain unclear.
Sympathetic nervous system hyperactivity is a salient char-
acteristic of chronic HF and is known to be associated with
dysfunctional cardiac b-ARs [10,15]. Abnormalities in SNS
function have also been related to DM. In fact, sympathetic
hyperactivation can cause or be the consequence of insulin
resistance/hyperinsulinaemia and, in patients with autonomic
neuropathy, early impairment of vagus nerve function can be
responsible of relative predominance of sympathetic activity
[23,24]. Despite some line of evidence indicates that with the
progression of diabetic neuropathy, circulating catecholamine
levels tend to decrease to normal or under normal levels [25,26],
other preclinical and clinical studies show that DM is associ-
ated with increased sympathetic tone and reduced b-AR
responsiveness [27,28]. This observation has been recently
confirmed in a population of HF patients where presence of
DM was associated to reduced b-AR sensitivity compared to
non-DMHF patients [29]. Consistently, in the present study, we
Figure 1 Lymphocyte GRK2 protein levels in HF patients with
and without DM. GRK2, G-protein-coupled receptors kinase 2;
HF, heart failure; DM, diabetes mellitus. Data are expressed as
mean  standard deviation.
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demonstrate that in DM patients with advanced HF, lympho-
cyte GRK2 protein levels are significantly higher compared to
HF patients without DM, reflecting more compromised b-AR
signalling/function.
Reduced cardiac 123I-MIBG uptake, reflecting cardiac sym-
pathetic activity, is a predictor of negative prognostic value in
patients with HF [30] and in DM patients without structural
cardiac disease [31]. Recently, the impact of DM on cardiac
sympathetic activity has been reported in patients with HF,
who showed significantly reduced 123I-MIBG uptake compared
to HF patients without DM, and this reduction predicted worse
outcome [18,32]. This latter finding is in line with the results of
the present study, as both lymphocyte GRK2 levels and 123I-
MIBG imaging parameters are detecting sympathetic abnor-
malities. In HF patients, there is an increased sympathetic drive
to the myocardium, which is mainly due to alterations in NE
synthesis, storage and release. Among the attributes of this
derangement, there is decreased cardiac NE uptake, which is
quantified by 123I-MIBG imaging [33]. As a consequence of
reduced reuptake, a higher concentration of NE is present in
the sympathetic synaptic cleft, leading to chronic hyperstimu-
lation and downregulation of myocardial b-ARs, which are
directly correlated to cardiac/lymphocyte GRK2 protein levels
[14,15]. Thus, lymphocyte GRK2 protein levels add important
information on cardiac b-AR function, whose status is impaired
in both DM and HF, and even more when these two conditions
are associated [15,31].
Moreover, preclinical studies indicate that altered glycemic
control, cardiac b-AR function and GRK2 expression are all
involved in the pathogenesis of HF-related insulin resistance.
In fact, it has been demonstrated that sustained b-AR stimu-
lation impairs cardiomyocytes responsiveness to insulin via
Akt signalling [34]. Further, HF-related cardiac GRK2 upreg-
ulation has been shown to interfere with insulin signalling,
promoting insulin resistance [20]. Importantly, GRK2 inhibi-
tion via gene therapy restores b-AR and insulin receptor
signalling/function with a consequent improvement in the
abnormalities of glucose metabolism observed in HF [20]. The
link between insulin signalling and b-AR function is also
corroborated by the observation that improvement of loading
ventricular conditions, induced by mechanical ventricular
assistance, restores insulin sensitivity and results in reduced
Table 2 Predictors of lymphocyte GRK2 levels in overall population
Univariate analysis Multivariate analysis
b 95% CI Lower 95% CI Upper P value b 95% CI Lower 95% CI Upper P value
Age 0009 0004 0014 0001 0003 0003 0009 0317
Gender 0109 0229 0012 0077 0055 0171 0061 0352
Ischaemic aetiology 0081 0073 0236 0300 – – – –
LVEF 0021 0028 0015 < 00001 0018 0025 0011 < 00001
NYHA class 0206 0065 0347 0004 0123 0287 0041 0140
Hypertension 0037 0098 0173 0589 – – – –
Hypercholesterolaemia 0044 0075 0162 0469 – – – –
Diabetes 0159 0048 0270 0005 0131 0030 0232 0011
GFR < 60 mL/min 0158 0045 0272 0006 0086 0030 0202 0145
ACE-I/ARBs 0071 0223 0081 0357 – – – –
b-blockers 0101 0213 0011 0076 0095 0204 0014 0087
Diuretics 0124 0000 0248 0049 0079 0043 0201 0204
CCBs 0105 0029 0238 0123 – – – –
NT-proBNP† 0179 0117 0242 < 00001 0084 0003 0165 0042
NE† 0237 0121 0353 < 00001 0120 0002 0238 0047
CI, confidence interval; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; GFR, glomerular filtration rate; ACE-I, angiotensin-con-
verting-enzyme inhibitor; ARBs, angiotensin receptor blockers; CCBs, Calcium channel blockers; NT-proBNP, N-terminal pro-brain natriuretic peptide; NE,
norepinephrine.
†Variables are continuous natural log transformed.
P value is referred to univariate and multivariate analysis against lymphocyte GRK2 protein levels.
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Table 3 Predictors of lymphocyte GRK2 levels in (a) nondiabetic and (b) diabetic patients
Univariate analysis Multivariate analysis
b 95% CI Lower 95% CI Upper P value b 95% CI Lower 95% CI Upper P value
(a)
Age 0013 0005 0021 0001 0003 0005 0010 0461
Gender 0160 0355 0035 0107 – – – –
Ischemic aetiology 0165 0058 0388 0146 – – – –
LVEF 0030 0041 0019 < 00001 0015 0026 0004 0008
NYHA class 0320 0112 0529 0003 0082 0308 0144 0477
Hypertension 0001 0193 0191 0991 – – – –
Hypercholesterolaemia 0053 0243 0138 0587 – – – –
GFR < 60 mL/min 0341 0169 0513 0000 0142 0034 0319 0113
ACE/ARBs 0015 0234 0203 0891 – – – –
b-blockers 0215 0387 0043 0015 0120 0278 0037 0133
Diuretics 0190 0003 0377 0046 0069 0110 0249 0446
CCBs 0235 0007 0464 0043 0117 0080 0315 0241
NT-proBNP† 0326 0233 0419 < 00001 0187 0074 0301 0001
NE† 0375 0200 0549 < 00001 0185 0022 0348 0026
(b)
Age 0004 0003 0010 0320 – – – –
Gender 0035 0176 0107 0629 – – – –
Ischemic aetiology 0007 0198 0213 0945 – – – –
LVEF 0013 0021 0004 0003 0011 0020 0003 0008
NYHA class 0039 0141 0219 0667 – – – –
Hypertension 0004 0192 0200 0967 – – – –
Hypercholesterolaemia 0111 0027 0249 0114 – – – –
GFR < 60 mL/min 0040 0178 0097 0563 – – – –
ACE/ARBs 0222 0424 0020 0031 0171 0372 0029 0094
b-blockers 0007 0143 0129 0916 – – – –
Diuretics 0021 0134 0176 0788 – – – –
CCBs 0034 0184 0116 0654 – – – –
NT-proBNP† 0044 0031 0120 0251 – – – –
NE† 0076 0068 0220 0298 – – – –
CI, confidence interval; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; GFR, glomerular filtration rate; ACE-I, angiotensin-con-
verting-enzyme inhibitor; ARBs, angiotensin receptor blockers; CCBs, calcium channel blockers; NT-proBNP, N-terminal pro-brain natriuretic peptide; NE,
norepinephrine.
†Variables are continuous natural log transformed.
P value is referred to univariate and multivariate analysis against lymphocyte GRK2 protein levels.
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lymphocyte GRK2 levels in patients with advanced HF
[35,36].
Current study
The current study provides novel insights on the association
between DM and HF, supporting the evidence derived from
preclinical studies of a relevant role of GRK2 in the interaction
between b-AR and insulin receptor signalling in HF. In fact,
patients with HF and DM show significantly higher blood
GRK2 protein levels, reflecting more compromised b-AR sig-
nalling, compared to non-DM patients, despite no differences
in demography, HF aetiology, LVEF, NYHA class, NE and NT-
proBNP.
To our knowledge, this was not reported before and is con-
sistent with previous studies reporting reduced 123I-MIBG
uptake in DM patients with HF, compared to non-DM patients
with HF [18,30], supporting the unfavourable prognostic asso-
ciation between DM and clinical outcome in HF patients.
Notably, the more deranged b-AR signalling pathway was not
reflected by NE levels that were similar between DM and non-
DM patients. Although no mechanistic relationship can be
derived, these findings generate the hypothesis that GRK2
overexpression is a pathogenetic determinant of the unfavour-
able clinical outcome of HF patients with DM and might further
impair insulin resistance in these patients.
Limitations
Lack of a control group of patients without HF is a limitation
of the study. In addition, previous studies demonstrating a
correlation between circulating and myocardial levels of
GRK2 and association between lymphocyte GRK2 levels and
cardiac b-AR status were all performed in end-stage heart
failure patients [14,36]. Thus, caution has to be made in
extending the results of previous studies to our patients with
less severe HF. Finally, lack of follow-up does not allow to
define the prognostic value of higher blood GRK2 levels in
DM patients with HF, which will deserve further investiga-
tion.
Conclusions
Coexistence of HF and DM results in significantly more ele-
vated lymphocyte GRK2 protein levels, likely reflecting more
compromised cardiac b-AR signalling/function, compared
with matched non-DM patients. This finding contributes to
explain the pathogenic relationship between HF and DM and
the worse prognosis observed in HF patients with DM com-
pared with HF non-DM patients. Future studies will be needed
to evaluate the prognostic value of lymphocyte GRK2 levels in
HF patients with DM and whether therapy-induced modifica-
tion of GRK2 levels predicts outcome.
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